Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report issued on Sunday morning. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners lowered their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Aspira Women’s Health stock opened at $0.83 on Friday. Aspira Women’s Health has a 52-week low of $0.67 and a 52-week high of $5.65. The firm has a 50 day moving average price of $0.84 and a two-hundred day moving average price of $1.22.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health as of its most recent filing with the SEC. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.